Tvardi Therapeutics (NASDAQ:TVRD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a strong sell rating to a sell rating in a report issued on Saturday morning,Wall Street Zen reports.

TVRD has been the topic of a number of other research reports. Raymond James Financial raised Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective on the stock in a research report on Wednesday, July 8th. Chardan Capital began coverage on Tvardi Therapeutics in a report on Tuesday, October 20th. They issued a “buy” rating for the company. UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price for the company in a research note on Wednesday, July 8th. Lucid Cap Mkts raised Tvardi Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.40.

Tvardi Therapeutics Stock Down 10.4%

NASDAQ:TVRD opened at $0.84 on Friday. Tvardi Therapeutics has a fifty-two week low of $0.84 and a fifty-two week high of $5.69. The company has a 50 day moving average price of $1.48 and a 200 day moving average price of $2.86.

Tvardi Therapeutics (NASDAQ:TVRD) last released its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). On average, sell-side analysts anticipate that Tvardi Therapeutics will post -2.35 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of TVRD. GSA Capital Partners LLP purchased a new stake in shares of Tvardi Therapeutics in the second quarter valued at about $34,000. Susquehanna International Group LLP purchased a new position in shares of Tvardi Therapeutics during the second quarter worth about $63,000. Finally, BlackRock Inc. purchased a new position in shares of Tvardi Therapeutics during the second quarter worth about $181,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development.

The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers.